Several druggable genetic alterations, including mutations in the kinase domain of the epidermal growth factor receptor (EGFR), KRAS G12C mutations, BRAF V600E mutations, MET exon14-skipping mutations, HER2/ErbB2 exon 20 mutations, and fusions of ALK, ROS1, RET, and NTRK, have been identified in NSCLC (mainly in LUAD) [5,6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.